I-Glycoera iphakamisa ama- $ 130m, ukugibela inzalo kumaprotheni amaprotheni

Ukuqalisa kwe-biotechnology okuthuthukayo kwezidakamizwa ezenzelwe ukuqeda amaprotheni anezinkinga atholakala ngaphandle kwamaseli aphakamise ama- $ 130 million ukuqala icala lawo lokuqala lomtholampilo.

Ukuqalisa, i-Glycoera, kuzosebenzisa imali ye-B Yezimali ye-B ukukhiqiza idatha yokuqala yomtholampilo ngohlelo lwayo lokuhola, ukwelashwa kwezifo azinakuvikelwa yi-GE8820. Kuhlose ukuletha umuthi wesibili wokuzivikela komzimba ekuhlolweni komuntu.

I-Glycoera Views GE8820 njengohlobo lwekhono elibanzi elingase lenze "ipayipi kumkhiqizo," kusho umongameli wenkampani kanye nesikhulu esiphezulu Amathayela wesidakamizwa i-IGG4, i-antibody ejikelezayo engavikela ukumelana ne-allergies, kepha ukungasebenzi kahle futhi ahlasele izicubu zomzimba uqobo Izimo eziningi ze-autoimmune, phakathi kwazo ukuphazamiseka kwesikhumba pemphigus kanye ne-nephropathy eyisisekelo ye-membranous.

I-GE8820 iyimbangela embi - umuthi osebenzayo ophoqa umzimba ukuthi uchithe le igg4 enesici. Ingxenye eyodwa ye-molecule ibopha i-antibody futhi iyihuduli esibindini. Enye ingxenye bese ifaka phakathi i-receptor edonsa i-IGG4 ibe amaseli, lapho idonswa khona yiprotheni yangaphakathi yamaprothenilethi.

Ngokusho kwe-Glycoera, ukuhlolwa kwerediyo kukhombisile indlela engasusa ama-antibodies angasebenzi kahle e-IGG4 ngohlobo lokunemba olungabonwa nezinye izindlela. Ngokwenza kanjalo, i-GE8820 ingagwema imiphumela ebanzi ye-immunosupprespressive yeminye imishanguzo ye-autoimmune. Kungase futhi kudambise "umthwalo ohlelweni lwezempilo," kusho uKaundinya.

Iziguli ngokuvamile "ziphathwe, ziba ngcono, zilungile, bese zibuyela kulokho kubuyela emuva," kusho uKaundinya. "Indlela yethu ayinikezi nje kuphela iziguli ukuthi ziphile impilo engcono, nayo iqinisekile inomthelela kwezomnotho okungcono kwezempilo ngaphesheya kwebhodi."

I-Glycoera isedalule esidlangalaleni ezinye izinhlelo ezingemuva kwe-ge8820, kepha ayikacacilanga ukuthi yiziphi izifo ezihlosiwe. Inkampani ingahambisa isicelo sokuqala ukulingwa kwesidakamizwa sayo sesibili ngo-2026, Ngokwewebhusayithi yayo. 

I-Novo Holdrings LED Glycoera's Series B Round, okuhilelekile izingalo ze-ventle of roche kanye ne-bristol myers squibb, abalingani be-sofinnova namanye amafemu amaningana.

"Okuvelele ngempela ne-glycoera ukuthi wawunecala lokusebenzisa lapha lapho, isifo se-autoimmune, kunesidingo esilinganiselwe, isidingo esiphakeme sezempilo siqinile," kusho uNovo Holdrings uzakwethu uMax Klment. "Njengoba sibona indawo yesifo se-autoimmune yesifo ivela, abenzi bezokwelapha abanembile njenge-Glycoera bazofika phambili."

I-Glycoera iqanjwe nge-glycosylulation, inqubo lapho amaketanga kashukela anamathele kuwo amaprotheni. Le nkampani ifakwa ekhanda eWädenswil, eSwitzerland futhi ine-U.S. Footprint e-Newton, Massachusetts. Kwakuphelelwe yi-Swiss Biotech Liotech Liotech Liingotech Biologics in NgoJanuwari 2021, futhi waphakamisa cishe ama- $ 49 million Ngochungechunge luxhaso olunguNovemba.

Umjikelezo wakamuva wenkampani ubufakazi obengeziwe bokuqhubeka kwentshisekelo ngakho - obizwa ngokuthi amaprotheni ama-defaters, anikeza indlela yokuthola amaprotheni izindlela zokwelapha izidakamizwa azikwazi ukufinyelela. Ukucwaninga ngokuwohloka kwamaprotheni kususiwe kusukela Jika kwekhulu leminyaka, ukuvumela uhlu lwezinkampani ezisebenzisa Izindlela ezahlukahlukene kwa- Ukubhubhisa amaprotheni ayingozi.

Qaphela:Baphinde babuyiselwe e-biopharmadive. Uma kukhona noma yikuphi ukukhathazeka kwe-copyright, sicela uxhumane neqembu lewebhusayithi ukuze lisuswe.